Funding for this research was provided by:
Janssen Research and Development
Received: 24 January 2021
Accepted: 9 February 2021
First Online: 18 February 2021
Ethics approval and consent to participate
: This study was approved by the Duke Institutional Review Board (Pro00063296). All patients signed informed consent and willingly participated in this study.
: No identifiable patient information is disclosed in this publication. Patients signed informed consent for the clinical study which included potential publication of their data in aggregate.
: TZ has research funding (to Duke) from Pfizer, Janssen, Acerta, Abbvie, Novartis, Merrimack, OmniSeq, PGDx, Merck, Mirati, Astellas, and Regeneron; consulting/speaking with Genentech Roche, Exelixis, Genomic Health, and Sanofi Aventis; and advisory board/consulting with AstraZeneca, Bayer, Pfizer, Foundation Medicine, Janssen, Amgen, MJH Associates, Merck, BMS, Pharmacyclics, Seattle Genetics, Calithera, and Dendreon. Stock ownership/employment (spouse) from Capio Biosciences and Archimmune Therapeutics. RB and CR have employment and stock from Janssen. AA, RGA, DR, EB, SP, MAM, KW, MA, TO, PH, and JAS have no competing interests to disclose. DJG has research support (to Duke) from Acerta, Astellas, BMS, Bayer, Calithera, Exelixis, Janssen, Myovant, Pfizer, Novartis, Sanofi Aventis. Consulting income from Vizuri health sciences, UroToday, Sanofi, Pfizer, Nektar, Myovant, Modra, Merck, Ipsen, Flatiron, Exelixis, Capio, EMD Serono, BMS, Bayer, Astrazeneca, Astellas.AJA is a paid consultant with Pfizer, Astellas, Janssen, Bayer, Clovis, Astrazeneca, and Merck and receives research funding (to his institution) from Pfizer, Astellas, Janssen, Bayer, Dendreon, Novartis, Genentech/Roche, Merck, BMS, Astrazeneca, Constellation, Beigene.